TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03525652

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic vaccine
Description: The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine
Description: The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 Knockout T Cells
Description: PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
Study: NCT05174494

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of serum CRP and NT-proBNP
Description: All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of serum CRP and NT-proBNP
Description: All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP
Study: NCT00039026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT03323216

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test
Description: The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test
Description: The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: Study specific questionnaire
Description: Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: Study specific questionnaire
Description: Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: Study specific questionnaire
Description: Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention.

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~- peripheral venous

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~- peripheral venous

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~- peripheral venous
Study: NCT03235921

Intervention type: DRUG
Group type: OTHER
Intervention: Nitroglycerin patch 5mg
Description: application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: no drug given to the control group
Study: NCT01538576

Intervention type: DRUG
Intervention: insulin aspart
Description: Prescribed by the physicians as a result of normal clinical practice
Study: NCT00925665

Intervention type: DEVICE
Intervention: Glidescope
Description: Patients are to be intubated using the Glidescope technique

Intervention type: DEVICE
Intervention: Macintosh laryngoscope
Description: Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
Study: NCT03925571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musicotherapy
Description: If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music...).
Study: NCT00633087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-deoxyglucose
Description: 30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
Study: NCT00935493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 0.1 mg po qhs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 0.5 mg po qhs
Study: NCT03912831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Administered subcutaneously.
Study: NCT00935493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po qhs
Study: NCT03003754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT) + Resistance Training (RT)
Description: Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
Study: NCT00711282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
Study: NCT01926444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001
Description: GIC-1001 oral tablet, white-coated, to be taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001
Description: GIC-1001 oral tablet, white-coated, to be taken with water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIC-1001
Description: GIC-1001 oral tablet, white-coated, to be taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001
Description: GIC-1001 oral tablet, white-coated, to be taken with water
Study: NCT02460068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fotemustine
Description: Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fotemustine and Ipilimumab
Description: Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Description: ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
Study: NCT03673280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
Study: NCT00652743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine GSK1562902A
Description: IM administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine GSK1562902A
Description: IM administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine GSK1562902A
Description: IM administration
Study: NCT02804633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: 1 gram every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of normal saline every 6 hours
Study: NCT00205153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy TEAM monitoring and counseling
Description: Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
Study: NCT04508933

Intervention type: DEVICE
Intervention: Extravascular Lung Water Index
Description: Measurement of the EVLWI

Intervention type: DEVICE
Intervention: Extravascular Lung Water Index
Description: Measurement of the EVLWI

Intervention type: DEVICE
Intervention: Pulmonary Vascular Permeability Index
Description: Measurement of the PVPI

Intervention type: DEVICE
Intervention: Pulmonary Vascular Permeability Index
Description: Measurement of the PVPI
Study: NCT00381719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: 3 mg Capsule twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: 20 mg Capsule twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: 60 mg Capsule twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Capsule twice daily for 4 weeks
Study: NCT05777668

Intervention type: RADIATION
Intervention: Volumetric modulated radiotherapy
Study: NCT00043745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Description: Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Description: Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Extract tablets
Description: Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
Study: NCT01945996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TExT MED
Description: educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TExT MED
Description: educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANS
Description: supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
Study: NCT02628041

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Iodine-125 seed implant
Description: Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose-rate Prostate Brachytherapy
Description: High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed.
Study: NCT00411385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin interferon alfa-2b
Description: 900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin interferon alfa-2b
Description: 900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a
Description: 180 micrograms Pegasys given subcutaneaously once a week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800mg/day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800mg/day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800mg/day for 24 weeks
Study: NCT02576795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
Study: NCT00592930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: flexibly dosed oral olanzapine 2.5 to 15 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04563351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anaesthetic techniques
Description: The patients were anesthetized with two different local anaesthetic techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic techniques
Description: The patients were anesthetized with two different local anaesthetic techniques.
Study: NCT00418457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia and opioids
Description: General anesthesia, usually with sevoflurane, and opioid analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional analgesia and propofol
Description: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
Study: NCT01631344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily physical activity consultation, Using the Stage of change model
Description: Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
Study: NCT01552941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberonics VNS System
Description: Active Implantable Electrical Vagal Nerve Stimulator
Study: NCT03460730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax
Description: 23-valent pneumococcal polysaccharide vaccine
Study: NCT02349529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention Group
Description: 6 group sessions

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list control
Description: Treatment as usual
Study: NCT03600571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial midpatellar (MMP) portal
Description: injection medial under horizontal patella midline was administrated with the lower limb extension

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial midpatellar (MMP) portal
Description: injection medial under horizontal patella midline was administrated with the lower limb extension

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anteromedial (AM) portal
Description: injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anteromedial (AM) portal
Description: injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
Study: NCT02381145

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG+RSV-supplementation
Description: Teavigo (\~300mg/d) Resveratrol (\~80mg/d)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00751933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Vivotif + Vaccine Dukoral + oats
Description: Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
Study: NCT03413033

Intervention type: OTHER
Intervention: Resonance tube
Description: Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
Study: NCT00751933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Vivotif + Vaccine Dukoral
Description: Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oats
Description: One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
Study: NCT03334539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL036 ophthalmic solution
Description: HL036 ophthalmic solution
Study: NCT03413033

Intervention type: OTHER
Intervention: Tongue trill
Description: Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
Study: NCT02971293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871 100 µg
Description: The subjects will receive one dose of AZD8871 100 µg single dose DPI.
Study: NCT03334539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL036 ophthalmic solution
Description: HL036 ophthalmic solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle solution
Description: Placebo vehicle solution
Study: NCT00967057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study: NCT03912831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Administered subcutaneously.
Study: NCT03055689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational telephone intervention
Description: Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
Study: NCT02971293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871 600 µg
Description: The subjects will receive AZD8871, 600 µg single dose DPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive Placebo single dose DPI.
Study: NCT01400139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate q24h film-coated tablets
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
Study: NCT00672295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, Paclitaxel, and Carboplatin
Description: Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m\^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn.
Study: NCT01150786

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium Supplement
Description: The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients in this arm took one placebo capsule daily for 12 weeks.
Study: NCT02501681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: priming solution during cardiovascular surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: priming solution during cardiovascular surgery